Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Led by National Institute on Drug Abuse (NIDA) · Updated on 2026-05-14

360

Participants Needed

11

Research Sites

147 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

CONDITIONS

Official Title

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 65 years
  • Meets DSM-5 criteria for moderate or severe methamphetamine use disorder
  • Interested in reducing or stopping methamphetamine use
  • Able to speak English and provide written informed consent
  • Self-reports methamphetamine use on 18 or more days in the past 30 days
  • Provides at least 2 positive methamphetamine urine samples out of up to 3 tests within 10 days
  • If female with uterus, not pregnant, agrees to use birth control and have pregnancy tests unless hysterectomy documented
  • Not physically dependent on opioids and opioid-free before naltrexone injection
  • Willing to follow all study procedures and medication instructions
  • Agrees to use a smartphone app to record daily medication dosing
Not Eligible

You will not qualify if you...

  • Has an acute medical or psychiatric disorder making participation unsafe
  • Has suicidal or homicidal thoughts needing immediate attention
  • Has history of epilepsy, seizures, head trauma with neurological effects, current eating disorders, or other seizure risk conditions
  • Has heart problems or abnormal ECG findings that prevent safe participation
  • Has Stage 2 hypertension (≥160/100 in 2 of 3 readings)
  • Has elevated liver function tests or bilirubin above limits
  • Has low platelet count (<100,000/microliter)
  • Has body size preventing safe injection of the study drug
  • Allergic or sensitive to study medications or components
  • Participated in pharmacological or behavioral treatment for methamphetamine use disorder in past 6 months
  • Used investigational drugs in past 30 days
  • Taken naltrexone or bupropion in past 30 days
  • Currently enrolled in formal substance use disorder treatment
  • Taking medications that may interact negatively with study drugs
  • Has alcohol or sedative use that prevents safe participation
  • Requires opioid medications during study
  • Has planned surgery during study
  • Is in jail, prison, inpatient facility, or has legal or unstable living situations preventing participation
  • If female with uterus, is pregnant, breastfeeding, or planning conception

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States, 72205

Actively Recruiting

2

University of California Los Angeles

Los Angeles, California, United States, 90038

Actively Recruiting

3

University of California at San Diego

San Diego, California, United States, 92037

Actively Recruiting

4

Indiana University

Indianapolis, Indiana, United States, 46202

Actively Recruiting

5

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

6

University of Minnesota

Minneapolis, Minnesota, United States, 55415

Actively Recruiting

7

CODA

Portland, Oregon, United States, 97214

Active, Not Recruiting

8

MUSC/BHS

Pickens, South Carolina, United States, 29671

Active, Not Recruiting

9

University of Tennessee

Memphis, Tennessee, United States, 38119

Actively Recruiting

10

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75247

Actively Recruiting

11

University of Virginia

Charlottesville, Virginia, United States, 22903

Actively Recruiting

Loading map...

Research Team

J

Jennifer Wong, PhD

CONTACT

J

Jana Drgonova, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here